The following companies’ shares may have unusual moves in European trading. Stock symbols are in parentheses.
The Stoxx Europe 600 Index rose 2.1 percent to 242.20. The Stoxx 50 Index gained 1.7 percent to 2,303.72. The Euro Stoxx 50 Index, a benchmark measure for nations using the euro, advanced 2.5 percent to 2,347.94.
Adidas AG (ADS) : The sportswear maker’s Chief Executive Officer Herbert Hainer said Europe’s debt crisis won’t halt the growth of the sporting-goods market. He forecast higher earnings next year as the company expands in Russia and China. The shares gained 0.3 percent to 51.52 euros.
Alstom SA (ALO) : The maker of high-speed trains’ Chief Executive Officer Patrick Kron said the 2012 fiscal year operating margin has “no chance to be at the higher end of” the 7 percent to 8 percent forecast for next year. The shares jumped 5.8 percent to 27.50 euros.
Bollore (BOL) : The French holding company controled by billionaire Vincent Bollore said its third-quarter sales rose 21 percent to 2.17 billion euros ($3 billion). The company sees fiscal year 2011 performance in line with the first half of the year. The shares rallied 2.7 percent to 166.05 euros.
BP Plc (BP/) : Europe’s second-biggest oil company is operating a coker at reduced rates at the Whiting refinery in Indiana during maintenance on the unit, according to a person familiar with operations at the plant. The shares gained 0.9 percent to 456.70 pence.
Corio NV (CORA) : The largest Dutch real-estate company, said nine-month profit rose by 4.7 percent as acquisitions, rent increases and extensions to buildings generated more revenue. The shares increased 0.8 percent to 35.29 euros.
Deutsche Boerse AG (DB1) (DB1 GY): The Frankfurt Stock Exchange owner and NYSE Euronext may look to overlapping business areas to find concessions they could offer to allay European regulators’ concerns over their plan to form the world’s largest exchange. The shares advanced 3.1 percent to 40.30 euros.
Eutelsat Communications (ETL) SA: The world’s third- largest satellite company said first-quarter revenue rose 3.4 percent and it expects an acceleration in “top-line” growth in the second half of the year. The shares climbed 1.5 percent to 30.51 euros.
ThromboGenics NV (THR) : The Belgian developer of the Ocriplasmin eye-disease treatment said its cash and short-term investments declined to 88.3 million euros at the end of September from 96.4 million euros on June 30. The shares rose 2.4 percent to 18.85 euros.
To contact the reporter on this story: Kaitlyn Kiernan in New York at firstname.lastname@example.org
To contact the editor responsible for this story: Nick Baker at email@example.com